Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Corgenix Announces Partnership with Health Diagnostic Laboratory

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
Corgenix Medical Corporation has announced a strategic partnership with Health Diagnostic Laboratory, Inc. for the development of a clinical Laboratory Developed Test.

The Laboratory Developed  Test (LDT) would be based on Corgenix’ patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.

Under terms of the multi-year agreement, HDL, Inc. has the rights to use Corgenix technology to develop, validate and offer a clinical LDT that may assist clinicians in predicting an increased risk for heart disease in various patient populations. The initial term of the agreement is three years, with annual renewals thereafter based on certain performance requirements.

“This strategic partnership continues our path to fully realize the commercial value of our technology,” said Douglass Simpson, President and CEO of Corgenix. “Our company looks forward to this beneficial partnership, which aims to expand the clinical utility of this advanced cardiac disease biomarker.”

“Our partnership with Corgenix fits perfectly with our strategy to develop best-of-breed biomarkers for the most comprehensive risk factor testing for cardiovascular disease and related diseases,” said Tonya Mallory, President and CEO of HDL, Inc.

LDT’s are at the leading edge of the personalized medicine movement, which includes testing that enables targeted pharmacologic treatment for, and prevention of, heart disease, cancer and other diseases.

Corgenix originally licensed the technology in 2002, and has applied this proprietary technology to the FDA-cleared anti-AtherOx® IgG test kit.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Corgenix Announces Initial Phase Completion of Clinical Trial of Rapid Test for Lassa Fever
First-to-market, point-of-care rapid diagnostic test based on recombinant antigen technology for the detection of Lassa viral hemorrhagic fever filed for CE Marking.
Tuesday, April 23, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
Small Molecules Lead to a Big Change in Reaction Outcomes
Scientists have changed the behaviour of a group of molecules involved in carbon-oxygen bond synthesis.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
Sanger Institute, St Jude Data-Sharing Agreement
Childhood cancer targeted by Sanger Institute and St Jude Children’s Research Hospital exchanges of cancer data
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Space Research Fighting Cancer
JPL and National Cancer Institute renew Big Data partnership that 'learns' data similarities.
Uncovering the Genetics Behind High Blood Pressure
Results suggest a role for blood vessels themselves in controlling blood pressure.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!